Handelsavisen
prelaunch
33
3347.HK HKEX IT Services & Consulting

Hangzhou Tigermed Consulting Co Ltd

HK$30,12
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
3,7B HKD
P/E
5,9x
EV / Rev
0,9x
Div yield
0,40 %
Op margin
18,0 %
ROE
3,7 %
Net margin
10,9 %
Debt / equity
0,09
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Hangzhou Tigermed Consulting Co Ltd operates as a contract research organization (CRO) providing drug discovery and development services, generating revenue through fee-for-service arrangements in the pharmaceutical and biotechnology sectors.

Business. Hangzhou Tigermed Consulting Co Ltd (3347.HK) is an IT services and consulting firm headquartered in Hangzhou. The company operates within the Technology sector, specifically providing IT consulting and other services. It is listed on the Hong Kong Stock Exchange under the ticker 3347.HK. Specific details regarding operating segments and geographic revenue mix are not available.

Classification58 %
SectorTechnology
Business sectorSoftware & IT Services
Industry groupIT Services & Consulting
ActivityIT Consulting & Other Services
Generated · model-assisted
Sell-side consensus
BUY11 analysts
8 buy3 hold0 sell
Avg 12m price target55,98

Analyst recommendations

11 analysts · consensus Buy
Buy8
Hold3
Sell0
12-month price target
55,98
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
100
composite score
Valuation
5,9x
P/E
Analysts
Buy
11 analysts · indicative
Ownership
not yet wired
Profitability
3,7 %
return on equity
Quality
54
quality score (0-100)

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 3347.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+1,9 %+2,4 %
    Energy+1,4 %+5,6 %+1,5 %
    Real Estate+0,7 %+4,1 %+0,8 %
    Health Care+0,7 %−0,6 %+0,7 %
    Consumer Discretionary+0,3 %+8,7 %+0,4 %
    Information Technology · THIS SECTOR−0,3 %+6,5 %−0,2 %
    Financials−0,3 %−4,4 %−0,2 %
    Consumer Staples−0,8 %+3,0 %−0,7 %
    Utilities−1,5 %−21,2 %−1,4 %
    Industrials−1,7 %−2,3 %−1,6 %
    Communication Services

    Developing storylines

    No tracked sagas currently linked to 3347.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-07-07 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
    • Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
    • Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Score breakdown100
    Valuation+45
    Profitability+32
    Sentiment+30
    Risk penalty−3

    Synthesis

    Business

    Hangzhou Tigermed Consulting Co Ltd (3347.HK) is an IT services and consulting firm headquartered in Hangzhou. The company operates within the Technology sector, specifically providing IT consulting and other services. It is listed on the Hong Kong Stock Exchange under the ticker 3347.HK. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification58 %
    SectorTechnology
    Business sectorSoftware & IT Services
    Industry groupIT Services & Consulting
    ActivityIT Consulting & Other Services
    AI synthesis
    GENERATED

    Hangzhou Tigermed Consulting Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.09 and a current ratio of 2.18, indicating strong short-term liquidity coverage. The company holds total assets of 28.36 billion CNY against total liabilities of 7.40 billion CNY, resulting in total equity of 20.96 billion CNY. Despite the strong balance sheet, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting that cash and equivalents are insufficient to cover the 1.82 billion CNY in long-term debt. Operating cash flow stands at 1.12 billion CNY, while free cash flow is 573.69 million CNY after capital expenditures of 214.37 million CNY.

    Profitability metrics indicate a compressed return profile relative to the asset base. The company reports a return on equity (ROE) of 3.68% and a return on assets (ROA) of 2.72%. With a net income of 887.89 million CNY on revenue of 6.83 billion CNY, the net margin is approximately 13%. The valuation snapshot reflects a depressed market perception, with a price-to-earnings (P/E) ratio of 5.91 and a price-to-book (P/B) ratio of 0.22, implying the market values the company at a significant discount to its tangible book value. The EV/EBITDA multiple of 5.02 and EV/Revenue of 0.9 further underscore the low valuation multiple applied by investors.

    Key takeaways
    • The company trades at a deep discount to book value (P/B 0.22) and earnings (P/E 5.91), suggesting significant market pessimism or a perceived decline in asset quality.
    • Strong liquidity coverage is evident with a current ratio of 2.18, but net cash is negative after accounting for total debt, creating a medium liquidity risk flag.
    • Profitability is modest with an ROE of 3.68% and ROA of 2.72%, indicating inefficient capital utilization relative to the equity base.
    • Analyst sentiment is positive with a mean recommendation of 2.00 and a mean price target of 54.39 CNY, implying ~47% upside from the current price.
    • Dilution risk is low, with no difference between basic and diluted share counts, and no recent equity issuance indicated.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Analysts project 51.2% upside to a mean price target of 55.98, reflecting strong market confidence in the stock.

    Net margin of 10.91% ranks above the 75th percentile of the IT Services cohort, demonstrating strong cost control.

    Free cash flow surged 353% year-over-year to 573.7 million CNY, highlighting improved cash generation capabilities.

    Debt-to-equity ratio of 0.09 is lower than the cohort median of 0.12, suggesting a conservative capital structure.

    BEAR CASE · 5

    Net income CAGR of -25.5% over four years signals a severe long-term decline in profitability trends.

    Revenue growth slowed to just 3.5% year-over-year, indicating stagnating top-line expansion in the latest period.

    Return on equity of 3.68% falls below the IT Services cohort median of 4.17%, showing weaker capital efficiency.

    Gross profit declined to 1.87 billion CNY in FY2026, down from 2.82 billion CNY in FY2024, eroding margins.

    Medium liquidity risk flags potential challenges in meeting short-term obligations, warranting caution for investors.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-04-28
    Q1 2026 · Quarter highlights

    Revenue ¥1.80B, +15,2% YoY; Operating income +180,8% YoY.

    Revenue¥1.80B+15,2 % YoY
    Operating income¥405.8M+180,8 % YoY
    Net income¥49.0M−70,4 % YoY
    Free cash flow
    EPS
    Operating cash flow¥317.7M+60,5 % YoY
    Financials
    Income statement
    Revenue¥1.80B
    Gross profit¥471.3M
    Operating income¥405.8M
    Net income¥49.0M
    Margins
    Gross margin26.2%
    Operating margin22.5%
    Net margin2.7%
    FCF margin
    Balance sheet
    Total assets¥28.80B
    Total liabilities¥7.88B
    Total equity¥20.92B
    Cash & equivalents¥2.17B
    Long-term debt¥1.73B
    Cash flow
    Operating cash flow¥317.7M
    CapEx-¥50.4M
    Free cash flow
    SBC
    P&L flow · revenue → net income
    Revenue ¥1.80BOperating costs ¥1.40BTax ¥356.8MNet income ¥49.0M
    Highlights
    • Revenue ¥1.80B, +15,2% YoY
    • Operating income +180,8% YoY
    • Net income −70,4% YoY
    • Net margin 2.7%

    Valuation TTM

    Market price
    HK$30,12
    Market cap
    HK$4.56B
    Enterprise value
    HK$6.38B
    P/E
    5.9x
    Non-GAAP P/E
    EV / Revenue
    0.9x
    EV / Op income
    5.0x
    EV / OCF
    5.7x
    P / B
    0.2x
    P / Tangible book
    0.2x
    Tangible book
    HK$20.96B
    Net cash
    -HK$1.82B
    Current ratio
    2.2
    Debt / equity
    0.1
    ROA
    2.7%
    ROE
    3.7%
    Cash conversion
    145.0%
    CapEx / revenue
    -3.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Diagnostic Instruments & Systems
    low · llm_fanout_v2
    Diagnostics
    low · llm_fanout_v2
    Life Sciences & Diagnostics Instruments
    low · llm_fanout_v2
    Life Sciences Research & Diagnostics
    low · llm_fanout_v2

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 35 %
    EPS
    Consensus EPS
    1,01
    Predicted surprise
    -0,06
    Beat probability
    35 %
    Analysts
    11
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    revision ratio -0,20 · as of 2026-07-06 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate1,01
    Revenueno estimateno estimate7,7B CNY
    Operating incomeno estimateno estimate963,9M CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output (TimesFM V1) — not investment advice. · generated 2026-07-07

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution11 analysts
    Strong buy3
    Buy5
    Hold3
    Sell0
    Strong sell0
    12-month price targetHK$54,39 · Median HK$54,05
    Low HK$28,56High HK$73,00
    Operating income · consensus963,9M CNY
    EPS surprise
    +2,6 %
    reported vs consensus · beat
    Revenue surprise
    −10,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$28,56
    MeanHK$55,98
    MedianHK$58,45
    HighHK$73,00
    SpotHK$30,12
    +85.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin18,0 %Above P75
    Net Margin10,9 %Above P75
    ROE3,7 %Below median
    Capex / Rev-3,0 %Below median
    D/E0,09Above median
    Cash Conv1,45Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Ev To Operating Income
      enterprise_value / operating_income
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Enterprise Value
      market_cap - net_cash
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Hangzhou Tigermed Consulting Co Ltd Market data — financials · 2026-07-06
    • Hangzhou Tigermed Consulting Co Ltd Market data — analyst estimates · 2026-07-06
    • Hangzhou Tigermed Consulting Co Ltd Market data — ESG · 2026-07-06

    Ownership & reference

    Leadership

    • Xiaoping YeExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    3347.HKCanonical
    HKEX · HKD

    Intel & risk

    PredictorBeat prob35 %Surprise-0,06Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-04-28 18:06 UTCEARNINGSQuarterly results — Q1 2026 Revenue CNY 1.80B · Net CNY 49.0M
    2026-03-30 18:01 UTCEARNINGSQuarterly results — Q4 2025 Revenue CNY 1.81B · Net CNY -132.5M
    2026-03-30 18:01 UTCEARNINGSAnnual results — FY 2026 Revenue CNY 6.83B · Net CNY 887.9M
    2025-10-28 14:03 UTCEARNINGSQuarterly results — Q3 2025 Revenue CNY 1.78B · Net CNY 637.1M
    2025-08-28 15:48 UTCEARNINGSQuarterly results — Q2 2025 Revenue CNY 1.69B · Net CNY 217.9M
    2025-04-28 14:45 UTCEARNINGSQuarterly results — Q1 2025 Revenue CNY 1.56B · Net CNY 165.5M
    2025-03-27 15:52 UTCEARNINGSQuarterly results — Q4 2024 Revenue CNY 1.54B · Net CNY -408.3M
    2025-03-27 15:52 UTCEARNINGSAnnual results — FY 2025 Revenue CNY 6.60B · Net CNY 405.1M
    2024-10-29 14:34 UTCEARNINGSQuarterly results — Q3 2024 Revenue CNY 1.71B · Net CNY 320.6M
    2024-08-30 06:38 UTCEARNINGSQuarterly results — Q2 2024 Revenue CNY 1.70B · Net CNY 257.8M
    2024-03-28 16:47 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 7.38B · Net CNY 2.03B
    2023-03-29 13:39 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 7.09B · Net CNY 2.02B
    2022-03-10 19:10 UTCEARNINGSAnnual results — FY 2022 Revenue CNY 5.21B · Net CNY 2.88B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-07 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage